JPS62148859A - Immunological measurement method for bacillus retained in bacterial exosporium - Google Patents

Immunological measurement method for bacillus retained in bacterial exosporium

Info

Publication number
JPS62148859A
JPS62148859A JP28979985A JP28979985A JPS62148859A JP S62148859 A JPS62148859 A JP S62148859A JP 28979985 A JP28979985 A JP 28979985A JP 28979985 A JP28979985 A JP 28979985A JP S62148859 A JPS62148859 A JP S62148859A
Authority
JP
Japan
Prior art keywords
antibody
crude
haemophilus influenzae
antiserum
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP28979985A
Other languages
Japanese (ja)
Other versions
JPH0664065B2 (en
Inventor
Kazumi Horigome
堀米 一己
Hideaki Hoshino
英明 星野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NITSUSUI SEIYAKU KK
Nissui Pharmacetuical Co Ltd
Original Assignee
NITSUSUI SEIYAKU KK
Nissui Pharmacetuical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NITSUSUI SEIYAKU KK, Nissui Pharmacetuical Co Ltd filed Critical NITSUSUI SEIYAKU KK
Priority to JP60289799A priority Critical patent/JPH0664065B2/en
Publication of JPS62148859A publication Critical patent/JPS62148859A/en
Publication of JPH0664065B2 publication Critical patent/JPH0664065B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PURPOSE:To measure all influenza bacilli without overlooking regardless of types and to improve the degree of detection by bringing the antibody obtd. by immunizing the crude exosporium protein of the hemophilus influenza bacillus as an antigen into an animal into an immunological reaction with a specimen. CONSTITUTION:Any influenza bacilli are usable regardless of the types thereof. A specified amt. of the crude exosporium protein is inoculated intracutaneously, subcutaneously, intramuscularly, intraperitoneally and intraveneously to the animal or into the sole of a foot thereof several times, by which the antiserum is obtd. The immunogical reaction which is generally practised may be simply executed in the case of measuring the influenza bacilli in the specimen by using the antiserum (antibody) prepd. in the above-mentioned manner; for example, an enzyme immunoassay, radioimmunoassay, direct fluorescent antibody method, indirect fluorescent antibody method, reverse passive hemagglutination method, reverse passive latex agglutination method and coagulation method are usable.

Description

【発明の詳細な説明】 〔産業上の利用分野〕 本発明は菌体外膜保有菌の免疫学的測定法、更に詳細に
は、ヘモフイルス・インフルエンザ(Haemophi
lus 1nfluenzae)菌の粗性膜蛋白を抗原
として得られるポリクローナル抗体を使用して免疫学的
にヘモフィルス畢インフルエンザ菌ヲ測定する方法に関
する。
DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to an immunoassay method for bacteria harboring the outer membrane of a bacterial body, and more specifically, to an immunoassay method for bacteria harboring outer membranes of bacteria, and more specifically, for measuring Haemophilus influenzae (Haemophilus influenzae).
The present invention relates to a method for immunologically measuring Haemophilus influenzae using a polyclonal antibody obtained using the crude membrane protein of Haemophilus influenzae as an antigen.

〔従来の技術およびその問題点〕[Conventional technology and its problems]

従来、ヘモフイルス・インフルエンザ菌(以下、インフ
ルエンザ菌と称する)を測定する方法としては、当該菌
をホルマリン等で死菌化したものを家兎に免疫して得ら
れる抗血清を用いる免疫学的測定法が行われている。
Conventionally, the method for measuring Haemophilus influenzae (hereinafter referred to as Haemophilus influenzae) is an immunoassay method using antiserum obtained by immunizing rabbits with the bacteria killed with formalin etc. is being carried out.

しかしながら、インフルエンザ菌は夾膜血清屋別として
A% B、 C%D、 E及びFの6型に分類され、更
に実際の患者の呼吸器から分離されるインフルエンザ菌
の80〜90%は上記A〜F星の何れにも属さないノン
−タイパプルなものである。従って、従来の抗血清を使
用する測定法ではインフルエンザ菌の全てを測定テキな
いものであり、全てのインフルエンザ菌を測定しようと
すると、上記A−F型の6菌を抗原として得られる抗血
清を混合して使用しなければならないが、このようにす
ると個々の抗血清が希釈されてしまい検出感度が低下し
てしまうと共に、斯くしてもなおもノン−タイパズルな
インフルエンザ菌は検出できないという欠点があった0 従って、全てのインフルエンザ菌をもれなく、しかも感
度よく測定する方法が望まれていた。
However, Haemophilus influenzae is classified into 6 types, A% B, C% D, E, and F, based on the capsular serum type, and 80 to 90% of Haemophilus influenzae isolated from the respiratory tract of actual patients are of the A type. ~ It is a non-type group that does not belong to any of the F stars. Therefore, the conventional measurement method using antiserum is not suitable for measuring all Haemophilus influenzae, and in order to measure all Haemophilus influenzae, the antiserum obtained using the six A-F types as antigens is necessary. They must be used in combination, but in this way the individual antisera are diluted, reducing detection sensitivity, and even with this method, non-tied H. influenzae cannot be detected. Therefore, there has been a desire for a method that can measure all influenza bacteria with high sensitivity.

〔問題点を解決するだめの手段〕[Failure to solve the problem]

斯かる実状において、本発明者は鋭意研究を行った結果
、インフルエンザ菌の1株の粗列蛋白を抗原として得ら
れるポリクローナル抗体がインフルエンザ菌に対する特
異性が高く、シかも使用したインフルエンザ菌の型以外
の型でも又ノン−タイバプルのものでも、全てのインフ
ルエンザ菌をもれなく測定できることを見出し、本発明
を完成した。
Under these circumstances, the present inventor conducted intensive research and found that polyclonal antibodies obtained using the crude protein of a single strain of Haemophilus influenzae as an antigen have high specificity for Haemophilus influenzae, and that they may be used against strains of Haemophilus influenzae other than the type used. The present invention has been completed based on the discovery that all types of influenza germs, whether they are type or non-type, can be measured without exception.

すなわち、本発明は、ヘモフイルス・インフルエンザ菌
の粗列膜蛋白を抗原として動物に免疫して得られる抗体
を、被検体と免疫反応せしめることを特徴とするヘモフ
イルス・インフルエンザ菌の測定法を提供するものであ
る。
That is, the present invention provides a method for measuring Haemophilus influenzae, which is characterized in that an antibody obtained by immunizing an animal with a crude membrane protein of Haemophilus influenzae as an antigen is allowed to react with a subject. It is.

インフルエンザ菌の粗列膜蛋白はすでに公知のもので=
1)、例えば、インフエクション・アンド・イムニティ
ー(Infection and Tmmunit)’
)Vol、36. No、l、 80〜88頁、 19
82年に記載の方法によって単離される。ここで使用さ
れるインフルエンザ菌は型に関係なく何れのものも使用
できる。
The crude membrane protein of Haemophilus influenzae is already known =
1), for example, Infection and Immunity'
) Vol, 36. No.l, pp. 80-88, 19
It is isolated by the method described in 1982. Any type of Haemophilus influenzae can be used here, regardless of the type.

粗列膜蛋白を動物に免疫して抗体を調製する方法として
は、自体公知の方法が採用される。
As a method for preparing antibodies by immunizing animals with crude membrane proteins, methods known per se are employed.

動物としては家兎、山羊、緬羊、ろ馬、馬等の帽乳動物
が使用される。粗列膜蛋白の一定量を上記動物の皮肉、
皮下、筋肉内、腹腔内、静脈内又は足踏に数回接種する
ことによって抗血清を得る。
As animals, mammalian animals such as domestic rabbits, goats, sheep, horses, and horses are used. Animal skin, with a certain amount of crude column membrane protein,
Antisera are obtained by several subcutaneous, intramuscular, intraperitoneal, intravenous or foot inoculations.

このようにして調製した抗血清(抗体)を使用して、被
検体中のインフルエンザ菌を測定スるには、斯かる場合
に一般に行われている免疫反応を行えばよく、例えばエ
ンザイムイムノアツセイ、ラジオイムノアッセイ、直接
螢光抗体法1間接螢光抗体法、逆受身崩球凝集法、逆受
身ラテックス凝集法、コアギュレイション法カ使用され
る。
In order to measure Haemophilus influenzae in a subject using the antiserum (antibody) prepared in this way, it is sufficient to perform an immune reaction that is commonly used in such cases, such as an enzyme immunoassay. , radioimmunoassay, direct fluorescent antibody method, indirect fluorescent antibody method, reverse passive collapsing ball agglutination method, reverse passive latex agglutination method, and coagulation method.

〔発明の効果〕〔Effect of the invention〕

本発明は粗列膜蛋白よシ得られる抗体を使用するため、
型別に関係なく全てのインフルエンザ菌をもれなく測定
できると共に、インフルエンザ菌に特異的であり、しか
も検出度が高いという利点を有する。
Since the present invention uses antibodies obtained from crude membrane proteins,
It has the advantage of being able to measure all Haemophilus influenzae regardless of type, being specific to Haemophilus influenzae, and having a high degree of detection.

〔実施例〕〔Example〕

次に実施例を挙けて説明する。 Next, an example will be given and explained.

(1)菌体外膜蛋白抽出法 ヘモフィルスインフルエンザタイ7’6の1株t 、”
f−ス) 抽出物5 ”f/ d 、 ヘミン10 Z
IP/a%NAD100μl/−を加えたプレインハー
トインフュージョン液体培地37rKて18〜20時間
培養した菌を連続遠心にて菌体を回収し、150sdの
生理食塩水にて2回遠心洗浄後、200sjの塩化リチ
ウム抽出緩衝液(200mM塩化リチウム、100 m
M酢酸リチウム、pH6,0)に再浮遊させ、直径6鵡
のガラスピーズを約10Of[l!l加えたロータリー
攪拌機により、45Cにて3時間激しく攪拌し、12.
000>115分間遠心し、さらに25,000 X 
120分間遠心した上清を精製水に対して透析したもの
を粗列膜蛋白とした。
(1) Bacterial outer membrane protein extraction method Haemophilus influenzae thailand 7'6 strain 1.
f-s) Extract 5” f/d, Hemin 10 Z
Bacteria were cultured for 18 to 20 hours in plain heart infusion liquid medium 37rK supplemented with 100 μl/- of IP/a% NAD, and the cells were collected by continuous centrifugation, centrifugally washed twice with 150 sd physiological saline, and then incubated at 200 sj. of lithium chloride extraction buffer (200 mM lithium chloride, 100 m
Resuspended in M lithium acetate, pH 6.0), approximately 10 of [l! Stir vigorously for 3 hours at 45C with a rotary stirrer added, 12.
Centrifuge for 000>115 minutes, then 25,000
The supernatant after centrifugation for 120 minutes was dialyzed against purified water and used as crude membrane protein.

(2)  粗性膜蛋白抗血清作製と精製上記(1)項で
得られた粗列膜蛋白2fng(蛋白濃度)を1回の接種
量とし、家兎の静脈内に1週間に1回4週連続接種した
後、さらに4週の間隔をおいて1週間に1回、3週連続
接種して免疫を行なう。最終免疫の1週間後に血液を採
取し常法によって抗血清を得た。この抗血清を硫安塩析
、イオン交換してIgG分画を調製し、抗粗外膜蛋白抗
体とした。
(2) Preparation and Purification of Crude Membrane Protein Antiserum 2fng (protein concentration) of the crude membrane protein obtained in the above (1) is used as an inoculation amount, and intravenously administered to domestic rabbits once a week for 4 times. After continuous weekly vaccination, immunization is performed by inoculating once a week for 3 consecutive weeks at intervals of 4 weeks. One week after the final immunization, blood was collected and antiserum was obtained by a conventional method. This antiserum was subjected to ammonium sulfate salting out and ion exchange to prepare an IgG fraction, which was used as an anti-crude outer membrane protein antibody.

(3)  抗粗外膜蛋白抗体を利用したELISA法1
)固相化抗体の調製 上記(2)項による抗粗外膜蛋白抗体(IgG分画)を
0.05 M炭酸緩衝液(pH9,6)で希釈して50
μi/−の抗体溶液となし、これをEIA用マイクロプ
レートの各ウェルに200μj宛分注した。このマイク
ロプレートを4〜10Cで24時間放置した後にウェル
内容物を蒸留水で洗浄した。次いで、各ウェル内に2%
牛アルブミン含有燐酸緩衝食塩水(p[(7,2)を2
00pJ宛分注し、4〜10Cで更に24時間放置して
同相化抗体とした。
(3) ELISA method 1 using anti-crude outer membrane protein antibody
) Preparation of immobilized antibody Dilute the anti-crude outer membrane protein antibody (IgG fraction) obtained in item (2) above with 0.05 M carbonate buffer (pH 9,6) to 50%
A μi/− antibody solution was prepared, and 200 μj of this was dispensed into each well of an EIA microplate. After the microplate was left at 4-10C for 24 hours, the contents of the wells were washed with distilled water. Then in each well 2%
Bovine albumin-containing phosphate buffered saline (p[(7,2) 2
00 pJ and left at 4 to 10 C for an additional 24 hours to obtain a homophasized antibody.

同、この固相化抗体は使用に先立ち蒸留水で洗浄される
Similarly, this immobilized antibody is washed with distilled water before use.

2)標識抗体の調製 アルカリホスファターゼ(仔牛小腸起源、ベーリンガー
社製)3岬を1mM塩化マグネシウム含有0.1M、N
、N−ビス(2−ヒドロキシエチル)−グリシンi衝1
(pH8,5)1づに添加して溶解させ、次いで過沃素
酸カリウム20■を添加し37cで2時間放置した。そ
の後に800回転で5分間遠心して不溶物を除去し、上
清を1 mM塩化マグネシウム含有0.1 M炭酸緩衝
液(pH9,5)で−晩透析した。次いで上記(2)項
による抗粗外膜蛋白抗体(IgG分画)15■を添加し
、4〜10tZ”で14日間放置し、2%牛アルブミン
含有燐酸緩衝食塩水で20倍に希釈した後に凍結保存し
た。
2) Preparation of labeled antibody Alkaline phosphatase (derived from calf small intestine, manufactured by Boehringer) 3-Misaki was added to 0.1M N containing 1mM magnesium chloride.
, N-bis(2-hydroxyethyl)-glycine 1
(pH 8.5) was added 1 at a time to dissolve, and then 20 μm of potassium periodate was added and left at 37° C. for 2 hours. Thereafter, the mixture was centrifuged at 800 rpm for 5 minutes to remove insoluble materials, and the supernatant was dialyzed overnight against 0.1 M carbonate buffer (pH 9.5) containing 1 mM magnesium chloride. Next, 15 μl of the anti-crude outer membrane protein antibody (IgG fraction) according to item (2) above was added, left at 4 to 10 tZ'' for 14 days, and diluted 20 times with phosphate buffered saline containing 2% bovine albumin. Stored frozen.

尚、使用時には2%牛アルブミン含有燐酸緩衝食塩水で
所用希釈率のものとなす。
When used, dilute it to the required dilution rate with phosphate buffered saline containing 2% bovine albumin.

3)測定法 上記(31−1)で準備された抗粗外膜蛋白抗体(Ig
G分画)が固相化されたマイクロプレートを蒸留水にて
洗浄した、上記(1)項で得られた粗列膜蛋白そのもの
又は上記(1)項で使用した液体培地で培養された菌体
を含む培養液を200μ!宛分注した。このマイクロプ
レートを室温で2時間反応後、蒸留水にて洗浄した後、
上記(3)−2)で調製された標識抗体の希釈液200
μlを添加し、室温で1時間反応させた後に内容物を蒸
留水で洗浄する。次いでアルカリホスファターゼ活性測
定用基質液(45mMフェニル燐酸2ナトリウム及び2
mM4−アミノアンチピリン含有0.025M炭酸緩衝
液、pH10,2)を200μ!添加し、室温で20分
間反応させる。その後に発色液(0,8チ過沃素酸ナト
リウム)100μ!、を添加して酵素反応を停止させる
と共に発色を生じさせ、抗原抗体反応に関与したアルカ
リホスファターゼの活性を、ELISAアナライザーに
よυ、波長500 rLtnで吸光度測定を行う。
3) Assay method Anti-crude outer membrane protein antibody (Ig
A microplate on which G fraction was immobilized was washed with distilled water, and the crude membrane protein itself obtained in item (1) above or bacteria cultured in the liquid medium used in item (1) above 200 μ of culture solution containing the body! Dispense to address. After reacting this microplate at room temperature for 2 hours, washing with distilled water,
Diluted solution of labeled antibody prepared in (3)-2) above 200
After adding μl and reacting for 1 hour at room temperature, the contents are washed with distilled water. Next, a substrate solution for measuring alkaline phosphatase activity (45 mM disodium phenylphosphate and 2
0.025M carbonate buffer containing mM 4-aminoantipyrine, pH 10.2) at 200μ! Add and react for 20 minutes at room temperature. After that, 100μ of coloring solution (0,8 sodium periodate)! is added to stop the enzymatic reaction and generate color, and the activity of alkaline phosphatase involved in the antigen-antibody reaction is measured by absorbance at a wavelength of 500 rLtn using an ELISA analyzer.

(4)結果 1)臨床分離株による検討を行なう前に、ヘモフイルス
・インフルエンザ菌の莢膜血清型別A−Fの6株、莢膜
型別A−F’の何れにも属さないノンタイパプルなイン
フルエンザ菌8株、さらに上記(1)項で粗列膜蛋白を
得た菌も含めた莢膜型別タイプb(臨床分離株)4株に
ついて、上記(31−1)項のrilll定法」に記載
の操作手順に従い、ELTSA法による測定を行ない表
−1の成績を得た。
(4) Results 1) Before conducting an investigation using clinically isolated strains, six strains of Haemophilus influenzae capsular serotypes A-F and non-type influenza strains that do not belong to any of the capsular serotypes A-F' were detected. 8 strains of bacteria, and 4 strains of capsular type B (clinical isolates), including the bacteria from which crude membrane protein was obtained in section (1) above, were described in "Rill's standard method" in section (31-1) above. Measurements were carried out using the ELTSA method in accordance with the operating procedure described in Table 1, and the results shown in Table 1 were obtained.

即ち、抗粗外膜蛋白抗体を利用したEL I SA法で
は()内の菌体培養液を測定した場合も、上記(1)項
の記載された方法によp18株の粗列膜蛋白そのものを
測定した場合も、いずれも陽性の結果を得た。また対照
として、従来の市販莢膜型別用抗血清と同様の方法でイ
ンフルエンザ菌タイプbの1株をホルマリン死菌化した
菌を家兎に免疫して得られた抗体を利用したELISA
法を行なったところ、市販莢膜型別抗血清と同様にタイ
プbの菌のみが反応しただけだった。
That is, in the ELISA method using an anti-crude outer membrane protein antibody, even when measuring the bacterial cell culture fluid in parentheses, the crude membrane protein of the p18 strain itself can be detected by the method described in (1) above. Positive results were also obtained in all cases of measurement. As a control, ELISA was conducted using an antibody obtained by immunizing rabbits with a formalin-killed strain of Haemophilus influenzae type B in the same manner as the conventional commercially available antiserum for capsular typing.
When the method was performed, only type B bacteria reacted, similar to the commercially available antisera for different capsular types.

このことからも本発明による方法は、全てのインフルエ
ンザ菌を測定することに有効であることが判る。
This also shows that the method according to the present invention is effective in measuring all Haemophilus influenzae.

表−1 壷粗外膜蛋白を測定した吸光値 栗※菌体培養液を測定した吸光値 11)生化学的性状によシヘモフイルス・インフルエン
ザ菌と同定された臨床分離株179株について、上記(
1)項で使用した液体培地で培養された菌体を含む培養
液について、上記(31−1)項の「測定法」に記載の
操作手順に従い、表−2の成績を得た。即ち、抗粗外膜
蛋白抗体を利用したELISA法では、179株中1?
2株(96%)が陽性の結果を得た。対照として従来の
市販莢膜型別用抗血清と同様の方法で、インフルエンザ
菌タイプbの1株をホルマリン死菌化した薗を家兎に免
疫して得られた抗体を利用したELtSA法を行なった
ところ、市販の生菌凝集試験で二社の製品でタイプbと
同定されたものだけが陽性となった。またインフルエン
ザ菌以外の細菌111株についても同様の測定を行なっ
たが全ての株で陰性の結果を得た。
Table 1: Absorbance values measured for crude outer membrane protein of the jar Chestnut *Absorbance values measured for bacterial cell culture 11) Regarding the 179 clinical isolates identified as Haemophilus influenzae by biochemical properties,
Regarding the culture solution containing the bacterial cells cultured in the liquid medium used in section 1), the results shown in Table 2 were obtained according to the operating procedure described in "Measurement method" in section (31-1) above. That is, in the ELISA method using an anti-crude outer membrane protein antibody, 1 out of 179 strains was detected.
Two strains (96%) yielded positive results. As a control, we performed the ELtSA method using an antibody obtained by immunizing a rabbit with a formalin-killed strain of Haemophilus influenzae type B using the same method as a conventional commercially available antiserum for capsular typing. However, in a commercially available live bacteria agglutination test, only the products from the two companies that were identified as type B tested positive. Similar measurements were also performed on 111 strains of bacteria other than Haemophilus influenzae, and negative results were obtained for all strains.

このことからも本発明による方法は、インフルエンザ菌
に対する特異性が高く、シかも全てのインフルエンザ菌
を測定するととに有効であることが判る。
This also shows that the method according to the present invention has high specificity for Haemophilus influenzae and is effective in measuring all Haemophilus influenzae.

※l デンカ主灯製 莢膜血清型別用抗血清※※II 
 Difco製  莱膜血清塑別用抗血清以上 手続補正書(自発) 昭和61年 4月25日
※l Antiserum for capsular serotyping made by Denka Main Light ※※II
Difco-produced antiserum for plasticizing the capsule serum (voluntary) April 25, 1986

Claims (1)

【特許請求の範囲】[Claims] 1、ヘモフイルス・インフルエンザ菌の粗外膜蛋白を抗
原として動物に免疫して得られる抗体を、被検体と免疫
反応せしめることを特徴とするヘモフイルス・インフル
エンザ菌の測定法。
1. A method for measuring Haemophilus influenzae, which is characterized by making an antibody obtained by immunizing an animal with the crude outer membrane protein of Haemophilus influenzae Haemophilus influenzae as an antigen react with the subject.
JP60289799A 1985-12-23 1985-12-23 Immunological assay for outer membrane-bearing bacteria Expired - Lifetime JPH0664065B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP60289799A JPH0664065B2 (en) 1985-12-23 1985-12-23 Immunological assay for outer membrane-bearing bacteria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60289799A JPH0664065B2 (en) 1985-12-23 1985-12-23 Immunological assay for outer membrane-bearing bacteria

Publications (2)

Publication Number Publication Date
JPS62148859A true JPS62148859A (en) 1987-07-02
JPH0664065B2 JPH0664065B2 (en) 1994-08-22

Family

ID=17747913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60289799A Expired - Lifetime JPH0664065B2 (en) 1985-12-23 1985-12-23 Immunological assay for outer membrane-bearing bacteria

Country Status (1)

Country Link
JP (1) JPH0664065B2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0714649U (en) * 1993-08-12 1995-03-10 東洋電機製造株式会社 Vacuum suction chuck
CN102216781A (en) * 2009-01-07 2011-10-12 大塚制药株式会社 Method for assaying all types of influenza viruses
JP2014523525A (en) * 2011-06-06 2014-09-11 ネイションワイド チルドレンズ ホスピタル, インコーポレイテッド Detection method for diagnosis of chronic sinusitis based on proteomics
US10620221B2 (en) 2015-03-30 2020-04-14 Entvantage Diagnostics, Inc. Devices and assays for diagnosis of sinusitis
US10921320B2 (en) 2015-03-30 2021-02-16 Entvantage Diagnostics, Inc. Devices and methods for diagnosis of sinusitis
US11650213B2 (en) 2015-03-30 2023-05-16 Entvantage Diagnostics, Inc. Devices and assays for diagnosis of viral and bacterial infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUMAN ANTIBODY RESPONSE TO INDIVISUAL OUTER MEMBRANE PROTEINS OF HAEMOPHILUS-INFLUENZAE TYPE B=1982 *
MONO CLONAL ANTIBODIES DIRECTED AGAINST A CELL SURFACE EPOSED OUTER MEMBRANE PROTEIN OF MAEMOPHILUS-INFLUENZAE TYPE B=1982 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0714649U (en) * 1993-08-12 1995-03-10 東洋電機製造株式会社 Vacuum suction chuck
CN102216781A (en) * 2009-01-07 2011-10-12 大塚制药株式会社 Method for assaying all types of influenza viruses
JP2014523525A (en) * 2011-06-06 2014-09-11 ネイションワイド チルドレンズ ホスピタル, インコーポレイテッド Detection method for diagnosis of chronic sinusitis based on proteomics
US10048261B2 (en) 2011-06-06 2018-08-14 The Ohio State University Proteomics based diagnostic detection method for chronic sinusitis
US10345300B2 (en) 2011-06-06 2019-07-09 Nationwide Children's Hospital, Inc. Proteomics based diagnostic detection method for chronic sinusitis
US10725040B2 (en) 2011-06-06 2020-07-28 Nationwide Children's Hospital, Inc. Proteomics based diagnostic detection method for chronic sinusitis
US10620221B2 (en) 2015-03-30 2020-04-14 Entvantage Diagnostics, Inc. Devices and assays for diagnosis of sinusitis
US10921320B2 (en) 2015-03-30 2021-02-16 Entvantage Diagnostics, Inc. Devices and methods for diagnosis of sinusitis
US11650213B2 (en) 2015-03-30 2023-05-16 Entvantage Diagnostics, Inc. Devices and assays for diagnosis of viral and bacterial infections

Also Published As

Publication number Publication date
JPH0664065B2 (en) 1994-08-22

Similar Documents

Publication Publication Date Title
Wall et al. The etiology of lobar pneumonia in the Gambia
US5262156A (en) Antigenic compositions and their use for the detection of Helicobacter pylori
Lancefield Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test
US5997862A (en) Therapeutic treatment of group A streptococcal infections
US5173294A (en) Dna probe for the identification of haemophilus influenzae
Olcen et al. The use of protein A‐containing staphylococci sensitized with anti‐meningococcal antibodies for grouping Neisseria meningitidis and demonstration of meningococcal antigen in cerebrospinal fluid
Courant et al. Biochemical and immunological heterogeneity of Bacteroides melaninogenicus
CN105203754B (en) Method and kit for fast detection of moraxella catarrhalis based on magnetic resolution and quantum dot labelling
JP2595133B2 (en) Immunostimulant and method for producing the same
Leinonen et al. The latex agglutination test for the diagnosis of meningococcal and Haemophilus influenzae meningitis
JPS62148859A (en) Immunological measurement method for bacillus retained in bacterial exosporium
Halonen et al. Rubella complement fixing antigen prepared by alkaline extraction of virus grown in suspension culture of BHK-21 cells
Poxton Serological identification of Bacteroides species by an enzyme-linked immunosorbent assay.
US7179611B2 (en) Mono-specific polyclonal antibodies and methods for detecting Clostridium difficile Toxin A
Maleewong et al. Excretory-secretory antigenic components of Paragonimus heterotremus recognized by infected human sera
EP0189841B1 (en) Enzymatic detection of bacterial capsular polysaccharide antigens
EP1053474B1 (en) Method for the determination of prosthetic infections
EP0389925A1 (en) A method for purifying an outer membrane protein of Haemophilus influenzae
Nakazawa et al. Diagnosis of Rhodococcus equi infection in foals by the agar gel diffusion test with protein antigen
RU2189253C1 (en) Diagnosticum for identification of escherichia coli 0157:h7 and method of its preparing
JP3483586B2 (en) Monoclonal antibodies against group C rotavirus inner core common antigen
SU1163635A1 (en) Serovar 59 vibrio nag 125/121 strain used for producing monospecific diagnostic serum
US20060127960A1 (en) Process for preparation of an agglutination reagent for rapid detection of typhoid
SU1668390A1 (en) Bacterial race vibrio nag of 078 serovar type usable for preparing monovar diagnostic serum
RU2310852C1 (en) EXPRESS-DIAGNOSIS METHOD FOR DIAGNOSING HEMOPHILIC INFECTION OF b TYPE IN CHILDREN